Table 1
Characteristics of Research papers accepted for the CARPHA conferences from 2006 to 2018 (1,512).
| CATEGORIES | FREQUENCY (#) | PERCENT (%) |
|---|---|---|
| Presentations | ||
| Orals | 784 | 51.9 |
| Posters | 728 | 48.2 |
| Country of Origin | ||
| Trinidad | 438 | 29.0 |
| Jamaica | 272 | 18.0 |
| Barbados | 227 | 15.0 |
| Other | 575 | 38.0 |
| Institution Affiliation | ||
| University | 1120 | 74.1 |
| Ministry of Health | 132 | 8.7 |
| Hospital | 107 | 7.1 |
| Other | 153 | 10.1 |
| Disease Areas | ||
| Cancer | 101 | 6.7 |
| CVD | 131 | 8.7 |
| Other | 1,270 | 84.0 |
| Collaboration | ||
| In-Country | 1,067 | 74.3 |
| Regional | 40 | 2.8 |
| International | 327 | 22.8 |
| Biomarkers Collected | ||
| Blood | 65 | 29.4 |
| Urine | 24 | 11.0 |
| Other body fluids | 09 | 4.1 |
| Other | 12 | 55.0 |
Figure 1
Persistent disparity in cancer and cardiovascular disease research for papers accepted at the CARPHA conferences from 2006 to 2018 (N = 1,512).
Table 2
Classification of methods for executing research accepted at CARPHA conferences from 2006 to 2018.
| STUDY DESIGN | OVERALL N = 1498 (%) | CANCER N = 101 (%) | CVD N = 131 (%) | OTHER N = 1266 (%) |
|---|---|---|---|---|
| CROSS-SECTIONAL | 658 (43.9) | 25 (24.8) | 60 (45.8) | 573 (45.3) |
| Qualitative | 90 (6.0) | 8 (7.9) | 3 (2.3) | 79 (6.2) |
| Retrospective | 88 (5.9) | 13 (12.9) | 9 (6.9) | 66 (5.2) |
| Lab-based | 77 (5.1) | 5 (5.0) | 2 (1.5) | 70 (5.5) |
| Audit | 75 (5.0) | 5 (5.0) | 7 (5.3) | 63 (5.0) |
| Case series | 69 (4.6) | 7 (7.0) | 5 (3.8) | 57 (4.5) |
| Prospective | 62 (4.1) | 1 (1.0) | 12 (9.2) | 49 (3.9) |
| Case-control | 43 (2.9) | 11 (10.9) | 5 (3.8) | 28 (2.2) |
| Surveillance | 44 (2.9) | 2 (2.0) | 2 (1.5) | 39 (3.1) |
| Program evaluation | 39 (2.6) | 2 (2.0) | 0 (0.0) | 37 (2.9) |
| Intervention | 28 (1.9) | 0 (0.0) | 3 (2.3) | 25 (2.0) |
| Environmental | 12 (0.8) | 0 (0.0) | 0 (0.0) | 12 (1.0) |
| Other* | 213 (14.2) | 22 (21.8) | 23 (17.6) | 168 (13.3) |
[i] * This figure contains other methods that were too small as standalone e.g. animal study, clinical trials, outbreak investigation, literature review, systematic review, registry based, metabolic, validation, reliability, randomised, health services, modelling, cost benefit analysis etc.
Table 3
Percentage of cancer and cardiovascular diseases research accepted at the CARPHA conferences from 2006 to 2018 (N = 1,502).
| AGREEMENT BETWEEN WRITTEN STUDY DESIGN & STEPS TAKEN | CANCER N (%) | CVD N (%) | OTHER N (%) |
|---|---|---|---|
| Agreement | 43 (42.6) | 53 (40.5) | 482 (38.0) |
| Disagreement | 23 (22.8) | 28 (21.4) | 280 (22.1) |
| Not Stated | 35 (34.7) | 50 (38.2) | 508 (40.0) |